Search research articles
Contact Us
Filters
Showing results (61-70 of 74) with videos related to
Page
of 8
Sort By:
Journal of Clinical Pharmacology
|
July 31, 2025
Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With Cobicistat
Niels Westra, Paul D Kruithof, Sander Croes, et al.
British Journal of Clinical Pharmacology
|
February 21, 2017
An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine
Anne Catrien Baakman, Ricardo Alvarez-Jimenez, Robert Rissmann, et al.
Clinical Pharmacology and Therapeutics
|
March 10, 2023
Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [<sup>18</sup> F]Canagliflozin in Patients with Type 2 Diabetes
Sjoukje van der Hoek, Antoon T M Willemsen, Ton Visser, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
European Journal of Hospital Pharmacy : Science and Practice
|
June 4, 2019
Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration
Titiaan E Post, Ingrid M C Kamerling, Richard C J M van Rossen, et al.
European Journal of Clinical Pharmacology
|
September 9, 2025
Hair analysis for monitoring adherence to inhaled respiratory medications: possibilities and limitations
Liz J A Cuperus, Wouter Ahmed, Johannes C C M In 't Veen, et al.
Journal of Medicinal Chemistry
|
November 8, 2021
GMP Compliant Synthesis of [<sup>18</sup>F]Canagliflozin, a Novel PET Tracer for the Sodium-Glucose Cotransporter 2
Sjoukje van der Hoek, Inês F Antunes, Khaled A Attia, et al.
British Journal of Clinical Pharmacology
|
April 23, 2021
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub> -acetylcholine receptor agonist: A randomized cross-over trial
Charlotte Bakker, Samantha Prins, Jan Liptrot, et al.
Diabetes, Obesity & Metabolism
|
November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Clinical Pharmacology and Therapeutics
|
December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 74) with videos related to
Sort By:
Page
of 8
Journal of Clinical Pharmacology
|
July 31, 2025
Osimertinib Cost Minimization in Non-Small Cell Lung Cancer (NSCLC) Treatment: Hypothesis Generation for a Population Pharmacokinetic Approach for Equivalent Dose Optimization of Osimertinib in Combination With Cobicistat
Niels Westra, Paul D Kruithof, Sander Croes, et al.
British Journal of Clinical Pharmacology
|
February 21, 2017
An anti-nicotinic cognitive challenge model using mecamylamine in comparison with the anti-muscarinic cognitive challenge using scopolamine
Anne Catrien Baakman, Ricardo Alvarez-Jimenez, Robert Rissmann, et al.
Clinical Pharmacology and Therapeutics
|
March 10, 2023
Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [<sup>18</sup> F]Canagliflozin in Patients with Type 2 Diabetes
Sjoukje van der Hoek, Antoon T M Willemsen, Ton Visser, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
March 31, 2023
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Sjoukje van der Hoek, Niels Jongs, Megumi Oshima, et al.
European Journal of Hospital Pharmacy : Science and Practice
|
June 4, 2019
Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration
Titiaan E Post, Ingrid M C Kamerling, Richard C J M van Rossen, et al.
European Journal of Clinical Pharmacology
|
September 9, 2025
Hair analysis for monitoring adherence to inhaled respiratory medications: possibilities and limitations
Liz J A Cuperus, Wouter Ahmed, Johannes C C M In 't Veen, et al.
Journal of Medicinal Chemistry
|
November 8, 2021
GMP Compliant Synthesis of [<sup>18</sup>F]Canagliflozin, a Novel PET Tracer for the Sodium-Glucose Cotransporter 2
Sjoukje van der Hoek, Inês F Antunes, Khaled A Attia, et al.
British Journal of Clinical Pharmacology
|
April 23, 2021
Safety, pharmacokinetics and pharmacodynamics of HTL0009936, a selective muscarinic M<sub>1</sub> -acetylcholine receptor agonist: A randomized cross-over trial
Charlotte Bakker, Samantha Prins, Jan Liptrot, et al.
Diabetes, Obesity & Metabolism
|
November 13, 2020
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Clinical Pharmacology and Therapeutics
|
December 18, 2020
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
Jeroen V Koomen, Jasper Stevens, George Bakris, et al.
Page
of 8